非小细胞肺癌中EML4-ALK融合基因的检测及临床意义
|
摘要
目的:为了对非小细胞肺癌的治疗提供参考依据,分析ALK融合基因的检测及临床意义。方法:根据随机原则的相关要求从2015年1月-2018年6月在笔者所在医院治疗的非小细胞肺癌患者中抽取60例作为研究对象,所有患者均通过二代测序技术(NGS)检测病理标本中的EML4-ALK融合基因,探讨EML4-ALK融合基因表达与各病理特征及临床指标的关系。结果:研究数据显示,60例患者中EML4-ALK融合基因阳性表达率为13.33%(8/60),而且阳性表达率在病理组织类型、既往吸烟史及肿瘤分化程度间比较差异有统计学意义(P<0.05)。结论:在非小细胞肺癌患者中EML4-ALK融合基因存在过度表达的情况,这与肿瘤的发生、发展密切相关,临床应重视对其检测。
Objective:To provide reference for the treatment of non-small cell lung cancer,and to analyze the detection and clinical significance of EML4-ALK fusion gene.Method:According to the relevant requirements of random principle,60 patients with non-small cell lung cancer treated in our hospital from January 2015 to June 2018 were selected as the research subjects.All patients were detected ALK fusion gene in pathological specimens by second generation sequencing(NGS),and the relationship between ALK fusion gene expression and pathological characteristics and clinical indicators was discussed.Result:The data showed that the positive expression rate of ALK fusion gene was 13.33%(8/60) in 60 patients,and there were significant differences in histopathological type,smoking history and tumor differentiation(P<0.05).Conclusion:Overexpression of ALK fusion gene exists in NSCLC patients,which is closely related to the occurrence and development of tumors.Clinical detection of ALK fusion gene shall be emphasized.
Objective:To provide reference for the treatment of non-small cell lung cancer,and to analyze the detection and clinical significance of EML4-ALK fusion gene.Method:According to the relevant requirements of random principle,60 patients with non-small cell lung cancer treated in our hospital from January 2015 to June 2018 were selected as the research subjects.All patients were detected ALK fusion gene in pathological specimens by second generation sequencing(NGS),and the relationship between ALK fusion gene expression and pathological characteristics and clinical indicators was discussed.Result:The data showed that the positive expression rate of ALK fusion gene was 13.33%(8/60) in 60 patients,and there were significant differences in histopathological type,smoking history and tumor differentiation(P<0.05).Conclusion:Overexpression of ALK fusion gene exists in NSCLC patients,which is closely related to the occurrence and development of tumors.Clinical detection of ALK fusion gene shall be emphasized.
引文
[1]林小梅,莫娟梅,邹敏,等.EGFR突变的非小细胞肺癌患者EML4-ALK融合基因的检测及其临床特征分析[J].中国病理生理杂志,2012,28(6):1135-1139.
[2]杨长绍,杨延龙,丁晓洁,等.非小细胞肺癌患者肿瘤组织多驱动基因联合检测及其临床意义[J].临床与实验病理学杂志,2017(11):1183-1187.
[3]张海燕,王捷,陈晓东,等.非小细胞肺癌患者EML4-ALK融合基因的检测及其临床病理特征分析[J].生物技术通讯,2015,26(3):377-380.
[4]马玲,单莉,张黎,等.新疆维吾尔族非小细胞肺癌患者EGFR-KRAS基因突变与临床病理特征的关系[J].实用临床医药杂志,2014,18(5):30-33.
[5]Liu Hua,Ma Yaohong,Liu Wen.Evaluation of the effect of early developmental supportive nursing on the growth and development of premature infants in NICU[J].Journal of Modern Integrated Chinese and Western Medicine,2014,23(2):203-205.
[6]Cristina T,Niki K,Vicente P,et al.IHC-FISH和RT-PCR检测对EML4-ALK重排的一致性[J].临床与病理杂志,2015,35(2):189-193.
[7]李筱妹,李志强.易瑞沙治疗晚期肺腺癌的临床疗效观察[J].北方药学,2016,13(1):8-9.
[8]高峨嵋,赵军,卓明磊,等.克唑替尼治疗晚期患者单中心回顾性分析[J].中国肺癌杂志,2016,19(3):161-168.
[9]程菊,茅矛.肺腺癌的驱动基因突变及相应的靶向治疗[J].中国医药生物技术,2016,11(2):151-158.
[10]董丹丹,徐钢,李芳华,等.肺腺癌EGFR-KRAS基因突变、ALK融合蛋白状态分析[J].实用癌症杂志,2017,32(9):1393-1397.
[11]刘静,姜桔红,顾莹莹,等.非小细胞肺癌患者ALK,EGFR及KRAS基因的检测及临床病理特征[J].临床与病理杂志,2017,37(6):1146-1152.
[12]Chen W,Zheng R,Zeng H,et al.Epidemiology of lung cancer in China[J].Thoracic Cancer,2015,6(2):209-215.
[13]Chen W,Zheng R,Baade P D,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[14]Solomon B J,Cappuzzo F,Felip E,et al.Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung can-cer:results from PROFILE 1014[J].J Clin Oncol,2016,34(24):2858-2865.
[15]Ettinger D S,Wood D E,Akerley W,et al.NCCN guidelines insights:non-small cell lung cancer,ver-sion4.2016[J].J Natl Compr Canc Netw,2016,14(3):255-264.
[16]钟山,张海萍,白冬雨,等.非小细胞肺癌组织中ALK、ROS1和RET融合基因的表达及其临床意义[J].中华病理学杂志,2015,44(9):639-643.
[2]杨长绍,杨延龙,丁晓洁,等.非小细胞肺癌患者肿瘤组织多驱动基因联合检测及其临床意义[J].临床与实验病理学杂志,2017(11):1183-1187.
[3]张海燕,王捷,陈晓东,等.非小细胞肺癌患者EML4-ALK融合基因的检测及其临床病理特征分析[J].生物技术通讯,2015,26(3):377-380.
[4]马玲,单莉,张黎,等.新疆维吾尔族非小细胞肺癌患者EGFR-KRAS基因突变与临床病理特征的关系[J].实用临床医药杂志,2014,18(5):30-33.
[5]Liu Hua,Ma Yaohong,Liu Wen.Evaluation of the effect of early developmental supportive nursing on the growth and development of premature infants in NICU[J].Journal of Modern Integrated Chinese and Western Medicine,2014,23(2):203-205.
[6]Cristina T,Niki K,Vicente P,et al.IHC-FISH和RT-PCR检测对EML4-ALK重排的一致性[J].临床与病理杂志,2015,35(2):189-193.
[7]李筱妹,李志强.易瑞沙治疗晚期肺腺癌的临床疗效观察[J].北方药学,2016,13(1):8-9.
[8]高峨嵋,赵军,卓明磊,等.克唑替尼治疗晚期患者单中心回顾性分析[J].中国肺癌杂志,2016,19(3):161-168.
[9]程菊,茅矛.肺腺癌的驱动基因突变及相应的靶向治疗[J].中国医药生物技术,2016,11(2):151-158.
[10]董丹丹,徐钢,李芳华,等.肺腺癌EGFR-KRAS基因突变、ALK融合蛋白状态分析[J].实用癌症杂志,2017,32(9):1393-1397.
[11]刘静,姜桔红,顾莹莹,等.非小细胞肺癌患者ALK,EGFR及KRAS基因的检测及临床病理特征[J].临床与病理杂志,2017,37(6):1146-1152.
[12]Chen W,Zheng R,Zeng H,et al.Epidemiology of lung cancer in China[J].Thoracic Cancer,2015,6(2):209-215.
[13]Chen W,Zheng R,Baade P D,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[14]Solomon B J,Cappuzzo F,Felip E,et al.Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung can-cer:results from PROFILE 1014[J].J Clin Oncol,2016,34(24):2858-2865.
[15]Ettinger D S,Wood D E,Akerley W,et al.NCCN guidelines insights:non-small cell lung cancer,ver-sion4.2016[J].J Natl Compr Canc Netw,2016,14(3):255-264.
[16]钟山,张海萍,白冬雨,等.非小细胞肺癌组织中ALK、ROS1和RET融合基因的表达及其临床意义[J].中华病理学杂志,2015,44(9):639-643.